Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ICPT's Cash to Debt is ranked higher than
93% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ICPT: No Debt )
ICPT' s 10-Year Cash to Debt Range
Min: 218.39   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ICPT's Equity to Asset is ranked higher than
95% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. ICPT: 0.91 )
ICPT' s 10-Year Equity to Asset Range
Min: -0.13   Max: 0.91
Current: 0.91

-0.13
0.91
Interest Coverage No Debt
ICPT's Interest Coverage is ranked higher than
76% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. ICPT: No Debt )
ICPT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 166.31
M-Score: -4.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7172.87
ICPT's Operating margin (%) is ranked lower than
54% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.26 vs. ICPT: -7172.87 )
ICPT' s 10-Year Operating margin (%) Range
Min: -6496.56   Max: -766.2
Current: -7172.87

-6496.56
-766.2
Net-margin (%) -16946.15
ICPT's Net-margin (%) is ranked lower than
54% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.01 vs. ICPT: -16946.15 )
ICPT' s 10-Year Net-margin (%) Range
Min: -16258.67   Max: -705.71
Current: -16946.15

-16258.67
-705.71
ROE (%) -207.49
ICPT's ROE (%) is ranked lower than
54% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. ICPT: -207.49 )
ICPT' s 10-Year ROE (%) Range
Min: -180.8   Max: -91.41
Current: -207.49

-180.8
-91.41
ROA (%) -128.97
ICPT's ROA (%) is ranked lower than
54% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. ICPT: -128.97 )
ICPT' s 10-Year ROA (%) Range
Min: -140.05   Max: -51.65
Current: -128.97

-140.05
-51.65
ROC (Joel Greenblatt) (%) -3730.51
ICPT's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.87 vs. ICPT: -3730.51 )
ICPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8893.89   Max: -3008.24
Current: -3730.51

-8893.89
-3008.24
» ICPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ICPT Guru Trades in Q1 2014

Jim Simons 6,500 sh (New)
Columbia Wanger 133,000 sh (New)
RS Investment Management 39,261 sh (New)
Andreas Halvorsen 454,917 sh (New)
Steven Cohen 5,171 sh (-99.59%)
» More
Q2 2014

ICPT Guru Trades in Q2 2014

Chuck Royce 360 sh (New)
Columbia Wanger 183,300 sh (+37.82%)
Steven Cohen 26,500 sh (unchged)
Jim Simons Sold Out
Andreas Halvorsen 208,077 sh (-54.26%)
RS Investment Management 3,214 sh (-91.81%)
Steven Cohen 6,123 sh (-99.51%)
» More
Q3 2014

ICPT Guru Trades in Q3 2014

RS Investment Management 7,016 sh (+118.29%)
Steven Cohen 37,300 sh (+40.75%)
Columbia Wanger 183,300 sh (unchged)
Chuck Royce Sold Out
Andreas Halvorsen Sold Out
» More
Q4 2014

ICPT Guru Trades in Q4 2014

Steven Cohen 300,200 sh (+704.83%)
Columbia Wanger 393,850 sh (+114.87%)
RS Investment Management Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ICPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intercept Pharmaceuticals Inc

Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST
According to GuruFocus Insider Data, the largest insider sells during the past week were: Intercept Pharmaceuticals Inc (ICPT), Target Corp (TGT), Aetna Inc (AET) and Ross Stores Inc (ROST). Read more...
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Intercept Pharmaceuticals Inc., Micron Technology Inc. and Facebook Inc. Read more...

Ratios

vs
industry
vs
history
P/B 26.20
ICPT's P/B is ranked lower than
57% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. ICPT: 26.20 )
ICPT' s 10-Year P/B Range
Min: 5.27   Max: 104.9
Current: 26.2

5.27
104.9
P/S 3398.40
ICPT's P/S is ranked lower than
63% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.38 vs. ICPT: 3398.40 )
ICPT' s 10-Year P/S Range
Min: 43.77   Max: 5778.25
Current: 3398.4

43.77
5778.25
EV-to-EBIT -51.38
ICPT's EV-to-EBIT is ranked lower than
51% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.80 vs. ICPT: -51.38 )
ICPT' s 10-Year EV-to-EBIT Range
Min: -215.1   Max: -15.7
Current: -51.38

-215.1
-15.7
Current Ratio 16.13
ICPT's Current Ratio is ranked higher than
97% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. ICPT: 16.13 )
ICPT' s 10-Year Current Ratio Range
Min: 4.69   Max: 16.62
Current: 16.13

4.69
16.62
Quick Ratio 16.13
ICPT's Quick Ratio is ranked higher than
98% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. ICPT: 16.13 )
ICPT' s 10-Year Quick Ratio Range
Min: 4.69   Max: 16.62
Current: 16.13

4.69
16.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.30
ICPT's Price/Net Cash is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ICPT: 29.30 )
ICPT' s 10-Year Price/Net Cash Range
Min: 8.85   Max: 17.2
Current: 29.3

8.85
17.2
Price/Net Current Asset Value 29.30
ICPT's Price/Net Current Asset Value is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ICPT: 29.30 )
ICPT' s 10-Year Price/Net Current Asset Value Range
Min: 8.65   Max: 16.61
Current: 29.3

8.65
16.61
Price/Tangible Book 27.40
ICPT's Price/Tangible Book is ranked lower than
53% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ICPT: 27.40 )
ICPT' s 10-Year Price/Tangible Book Range
Min: 7.27   Max: 19.24
Current: 27.4

7.27
19.24
Price/Median PS Value 2.00
ICPT's Price/Median PS Value is ranked higher than
62% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. ICPT: 2.00 )
ICPT' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 1.04
Current: 2

0.03
1.04
Earnings Yield (Greenblatt) -2.00
ICPT's Earnings Yield (Greenblatt) is ranked higher than
58% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ICPT: -2.00 )
ICPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.1   Max: 0
Current: -2

-3.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:I4P.Germany,
Intercept Pharmaceuticals Inc was incorporated in the State of Delaware on September 4, 2002. It is a biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat chronic liver disease utilizing its proprietary bile acid chemistry. The Company's product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions. The Company's product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA is a first-in-class product candidate that selectively binds to and induces activity in the farnesoid X receptor, or FXR, which it believes has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. PBC is a chronic autoimmune liver disease that, if inadequately treated, may eventually lead to cirrhosis, liver failure and death. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial that it anticipate will serve as the basis for seeking regulatory approval in the United States and Europe. The Company currently expects results from the trial to be available by mid-2014. OCA has received orphan drug designation in the United States and Europe for the treatment of PBC. The Company owns the rights to OCA outside of Japan and China, where it has exclusively licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to exclusively license OCA in certain other Asian countries. Some of the competitors are Eli Lilly, Exelixis, Inc. and Phenex Pharmaceuticals AG. Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those it is developing.
» More Articles for ICPT

Headlines

Articles On GuruFocus.com
Weekly Insider Sells Highlight: ICPT, TGT, AET, ROST Mar 30 2015 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc, Ross Stores Inc, Sally Beauty Holdings In Mar 30 2015 
Intercept Pharmaceuticals Announces Two New Sub-Groups for FLINT Trial Mar 24 2015 
Intercept Pharma’s Losses Widen, but Revenue Rises Mar 03 2015 
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Intercept Pharmaceuticals (ICPT) Obeticholic Acid Momentum, Gigamon (GIMO) Robust Revenue Growth Jan 30 2015 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc. Apr 14 2014 
President and CEO of Intercept Pharmaceuticals Inc. Mark Pruzanski Sold 37,500 Shares Jul 11 2013 
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT Jun 24 2013 

More From Other Websites
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 31 2015
Intercept Prices 1.2M Shares, Proceeds To Be ~$338.4M Mar 31 2015
9:14 am Intercept Pharma announces pricing of 1.2 mln share public offering of common stock,... Mar 31 2015
Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock Mar 31 2015
Genfit's French Fans Fume Following Failure of Fatty Liver Drug Mar 31 2015
Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Mar 31 2015
Intercept Pharmaceuticals Announces Proposed Offering of Common Stock Mar 31 2015
Intercept Pharmaceuticals Announces Proposed Offering of Common Stock Mar 31 2015
Insiders Join the Selling Party as Markets Post Steep Drop Mar 28 2015
Genfit sinks 31%, but CEO defends liver drug results Mar 27 2015
Drug trial setbacks Mar 27 2015
Genfit's Loss Is Gain For Intercept Pharmaceuticals Mar 27 2015
Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study Mar 27 2015
GenFit NASH Data Drives Up Rival Intercept Mar 26 2015
Healthcare Hedge Fund Orbimed’s Top Picks and New Move Mar 26 2015
Why Intercept Might Be A Better Bet Than Biogen Right Now Mar 24 2015
Can this fund deliver 300pc again over the next five years? Mar 24 2015
What We’re Trading Mar 20 2015
Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH Mar 20 2015
Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH Mar 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK